Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
J Pathol Transl Med. 2017 May;51(3):242-254. English. Review. https://doi.org/10.4132/jptm.2017.04.10
Shim HS , Choi YL , Kim L , Chang S , Kim WS , Roh MS , Kim TJ , Ha SY , Chung JH , Jang SJ , Lee GK , , .
Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Department of Pathology, Inha University School of Medicine, Incheon, Korea.
Department of Pathology, Inje University Ilsan Paik Hospital, Inje University, Goyang, Korea.
Department of Pathology, Konkuk University School of Medicine, Seoul, Korea.
Department of Pathology, Dong-A University College of Medicine, Busan, Korea.
Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Department of Pathology, Gachon University Gil Medical Center, Incheon, Korea.
Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea.
Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Department of Pathology, National Cancer Center, Goyang, Korea. gklee@ncc.re.kr
Abstract

Targeted therapies guided by molecular diagnostics have become a standard treatment of lung cancer. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are currently used as the best predictive biomarkers for EGFR tyrosine kinase inhibitors and ALK inhibitors, respectively. Besides EGFR and ALK, the list of druggable genetic alterations has been growing, including ROS1 rearrangements, RET rearrangements, and MET alterations. In this situation, pathologists should carefully manage clinical samples for molecular testing and should do their best to quickly and accurately identify patients who will benefit from precision therapeutics. Here, we grouped molecular biomarkers of lung cancers into three categories—mutations, gene rearrangements, and amplifications—and propose expanded guidelines on molecular testing of lung cancers.

Copyright © 2019. Korean Association of Medical Journal Editors.